Literature DB >> 28709963

Animal models of biliary injury and altered bile acid metabolism.

Valeria Mariotti1, Mario Strazzabosco2, Luca Fabris3, Diego F Calvisi4.   

Abstract

In the last 25years, a number of animal models, mainly rodents, have been generated with the goal to mimic cholestatic liver injuries and, thus, to provide in vivo tools to investigate the mechanisms of biliary repair and, eventually, to test the efficacy of innovative treatments. Despite fundamental limitations applying to these models, such as the distinct immune system and the different metabolism regulating liver homeostasis in rodents when compared to humans, multiple approaches, such as surgery (bile duct ligation), chemical-induced (3,5-diethoxycarbonyl-1,4-dihydrocollidine, DDC, α-naphthylisothiocyanate, ANIT), viral infections (Rhesus rotavirustype A, RRV-A), and genetic manipulation (Mdr2, Cftr, Pkd1, Pkd2, Prkcsh, Sec63, Pkhd1) have been developed. Overall, they have led to a range of liver phenotypes recapitulating the main features of biliary injury and altered bile acid metabolisms, such as ductular reaction, peribiliary inflammation and fibrosis, obstructive cholestasis and biliary dysgenesis. Although with a limited translability to the human setting, these mouse models have provided us with the ability to probe over time the fundamental mechanisms promoting cholestatic disease progression. Moreover, recent studies from genetically engineered mice have unveiled 'core' pathways that make the cholangiocyte a pivotal player in liver repair. In this review, we will highlight the main phenotypic features, the more interesting peculiarities and the different drawbacks of these mouse models. This article is part of a Special Issue entitled: Cholangiocytes in Health and Disease edited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Altered bile acid metabolism; Biliary injury; Cholangiocyte; Experimental models

Mesh:

Substances:

Year:  2017        PMID: 28709963      PMCID: PMC5764833          DOI: 10.1016/j.bbadis.2017.06.027

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  111 in total

Review 1.  Polycystic liver diseases: congenital disorders of cholangiocyte signaling.

Authors:  Mario Strazzabosco; Stefan Somlo
Journal:  Gastroenterology       Date:  2011-04-22       Impact factor: 22.682

2.  Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.

Authors:  Luca Fabris; Massimiliano Cadamuro; Romina Fiorotto; Tania Roskams; Carlo Spirlì; Saida Melero; Aurelio Sonzogni; Ruth E Joplin; Lajos Okolicsanyi; Mario Strazzabosco
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

3.  Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease.

Authors:  Joost P H Drenth; Rene H M te Morsche; Renate Smink; Juan S Bonifacino; Jan B M J Jansen
Journal:  Nat Genet       Date:  2003-02-10       Impact factor: 38.330

4.  Kidney cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal recessive polycystic kidney disease.

Authors:  Scott S Williams; Patricia Cobo-Stark; Leighton R James; Stefan Somlo; Peter Igarashi
Journal:  Pediatr Nephrol       Date:  2008-02-20       Impact factor: 3.714

5.  ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.

Authors:  Carlo Spirli; Stefano Okolicsanyi; Romina Fiorotto; Luca Fabris; Massimiliano Cadamuro; Silvia Lecchi; Xin Tian; Stefan Somlo; Mario Strazzabosco
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

Review 6.  Bile duct ligation: step-by-step to cholangiocyte inflammatory tumorigenesis.

Authors:  Maria-Angeles Aller; Jorge-Luis Arias; Isabel Prieto; Manuel Losada; Jaime Arias
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 2.566

Review 7.  Polycystin-1: a master regulator of intersecting cystic pathways.

Authors:  Sorin V Fedeles; Anna-Rachel Gallagher; Stefan Somlo
Journal:  Trends Mol Med       Date:  2014-01-31       Impact factor: 11.951

8.  Histochemical study of rat liver in alpha-naphthyl isothiocyanate (ANIT) induced cholestasis.

Authors:  V J Desmet; B Krstulović; B Van Damme
Journal:  Am J Pathol       Date:  1968-02       Impact factor: 4.307

Review 9.  Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection.

Authors:  Thamirys Guimarães Marques; Eleazar Chaib; Juliana Hamati da Fonseca; Ana Cecília Rodrigues Lourenço; Felipe Duarte Silva; Marcelo Augusto Fontenelle Ribeiro; Flavio Henrique Ferreira Galvão; Luiz Augusto Carneiro D'Albuquerque
Journal:  Acta Cir Bras       Date:  2012-08       Impact factor: 1.388

Review 10.  Animal models of biliary tract injury.

Authors:  Christoph H Österreicher; Michael Trauner
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

View more
  36 in total

Review 1.  Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-05       Impact factor: 5.187

2.  Mammalian Target of Rapamycin Complex 2 Signaling Is Required for Liver Regeneration in a Cholestatic Liver Injury Murine Model.

Authors:  Yi Zhou; Meng Xu; Pin Liu; Binyong Liang; Manning Qian; Haichuan Wang; Xinhua Song; Pranavanand Nyshadham; Li Che; Diego F Calvisi; Feng Li; Shumei Lin; Xin Chen
Journal:  Am J Pathol       Date:  2020-04-07       Impact factor: 4.307

Review 3.  Animal models to study bile acid metabolism.

Authors:  Jianing Li; Paul A Dawson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-18       Impact factor: 5.187

4.  Zebrafish as a Model to Study Cholestatic Liver Diseases.

Authors:  Duc-Hung Pham; Chunyue Yin
Journal:  Methods Mol Biol       Date:  2019

Review 5.  Liver regeneration biology: Implications for liver tumour therapies.

Authors:  Christopher Hadjittofi; Michael Feretis; Jack Martin; Simon Harper; Emmanuel Huguet
Journal:  World J Clin Oncol       Date:  2021-12-24

6.  Gut microbiome in liver pathophysiology and cholestatic liver disease.

Authors:  Shengmin Yan; Xiao-Ming Yin
Journal:  Liver Res       Date:  2021-08-08

7.  Cholestasis alters brain lipid and bile acid composition and compromises motor function in neonatal piglets.

Authors:  Nicole Lind Henriksen; Svend Høime Hansen; Matthew Domenic Lycas; Xiaoyu Pan; Thomas Eriksen; Lars Søndergaard Johansen; Richard R Sprenger; Christer Stenby Ejsing; Douglas G Burrin; Kerstin Skovgaard; Vibeke Brix Christensen; Thomas Thymann; Stanislava Pankratova
Journal:  Physiol Rep       Date:  2022-07

8.  HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis.

Authors:  Celine Hernandez; Peter Huebener; Jean-Philippe Pradere; Daniel J Antoine; Richard A Friedman; Robert F Schwabe
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

Review 9.  New insights on the role of vascular endothelial growth factor in biliary pathophysiology.

Authors:  Valeria Mariotti; Romina Fiorotto; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  JHEP Rep       Date:  2021-02-04

10.  A Novel Mouse Model of Acute-on-Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis.

Authors:  Shinji Furuya; Josepmaria Argemi; Takeki Uehara; Yuuki Katou; Derrick E Fouts; Bernd Schnabl; Laurent Dubuquoy; Abha Belorkar; Rajanikanth Vadigepalli; Hiroshi Kono; Ramon Bataller; Ivan Rusyn
Journal:  Alcohol Clin Exp Res       Date:  2019-11-28       Impact factor: 3.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.